Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Settles Rhode Island Opioid Claims, Seeks Nationwide Agreement

Generics Giant Will Pay The State $21m Over 13 Years Alongside $78.5m In Products

Executive Summary

Teva has settled with the state of Rhode Island on opioid-related claims and is set to pay the state $21m in cash and provide $78.5m worth of Narcan and Suboxone. The settlement was reached just as Rhode Island was preparing to take Teva to trial.

You may also be interested in...



Teva Inks $100m+ Deal To Settle West Virginia Opioid Claims

Teva has struck a further cash-and-medicines settlement agreement to resolve opioid-related claims in the US. A bench trial had been due to start in West Virginia by the end of this month, where Teva is to pay $75m over 15 years plus generic Narcan.

Teva Fails To Stay San Francisco Opioids Case Following Orange County Win

Fresh from inking a settlement agreement in Texas, Teva has seen a motion to stay opioids claims in San Francisco denied. A court in Northern California was not persuaded that a judgment in another part of the state would preclude claims.

Teva Inks Texas Opioids Settlement And Eyes J&J’s Nationwide ‘Formula’

Teva CEO Kåre Schultz has spoken at great length of the firm’s current standing with opioid-related matters, days after it reached a deal valued at $225m to resolve claims in the state of Texas. A nationwide deal is still top of the Israeli firm’s agenda, with a rough estimate of $3bn-$4bn suggested.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel